# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.66) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of ...
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Cal...
-SEC Filing
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio acros...
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax ...